XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in Austin, Texas.
| Revenue (TTM) | 300,000 |
| Gross Profit (TTM) | $3.36M |
| EBITDA | $-46.78M |
| Operating Margin | 0.00% |
| Return on Equity | -29.90% |
| Return on Assets | -19.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $4.21 |
| Price-to-Book | 0.45 |
| Price-to-Sales (TTM) | 12.23 |
| EV/Revenue | 24.05 |
| EV/EBITDA | -1.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -93.30% |
| Shares Outstanding | $30.49M |
| Float | $18.65M |
| % Insiders | 38.08% |
| % Institutions | 6.73% |
Volatility is currently expanding
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XBIT and any ticker you trade — then tracks every position and per-strategy win rate.
